forvisirvat

SP-624 (forvisirvat) is a once-daily oral sirtuin 6 (SIRT6) activator co-developed by privately held Sirtsei Pharmaceuticals and Arrivo BioVentures, currently in a Phase 2b/3 trial for major depressive disorder. The active study (NCT06254612, n=456, forvisirvat 20 mg vs placebo for 4 weeks) is closed to enrollment and in follow-up, with estimated primary completion in July 2026 [3]. The earlier Phase 2 (NCT04479852, n=319) was published by Raskin et al. in Current Medical Research and Opinion in late 2025 and reported a statistically significant Week 4 MADRS result on the overall population, but the headline was driven almost entirely by female participants [1]. If it works, SP-624 would be the first antidepressant to target a chromatin-modifying enzyme, a mechanism entirely distinct from both the monoamine reuptake inhibitors (SSRIs, SNRIs, bupropion) that dominate prescribing and the recently approved NMDA antagonists (Auvelity, approved 2022, and Spravato, approved 2019) that represent the field's first mechanistic diversification in decades.

SP-624 is a first-in-class small molecule, never approved anywhere [3]. Phase 1 single ascending dose and multiple ascending dose studies (SAD/MAD: the standard Phase 1 designs that escalate doses in small cohorts of healthy volunteers to find the safe range) in healthy volunteers established a tolerability and pharmacokinetic profile (how the drug is absorbed, distributed, and cleared) at a 20 mg once-daily oral dose [2]. A Phase 1 brain network analytics study (NCT06570369, n=26) compared healthy adults and MDD patients on imaging-derived network metrics [5]. The earlier Phase 2 (NCT04479852, n=319) tested forvisirvat 20 mg vs placebo for 4 weeks with a Week 4 MADRS readout. Results were published by Raskin et al. in 2025 [1, 4]. The larger ongoing Phase 2b/3 (NCT06254612, n=456) uses the same 20 mg dose and 4-week treatment window, with estimated primary completion in July 2026 [3, 9]. An exploratory Phase 1 in acutely psychotic schizophrenia patients (NCT04510298, n=27) was completed but no follow-on schizophrenia program has been announced [6]. No public FDA Breakthrough, Fast Track, or Orphan designation has been disclosed. No Phase 3 program has been announced. Sirtsei is privately held with no SEC filings of its own; the Vistagen Therapeutics 10-Ks surfaced by enrichment refer to PH94B (fasedienol), a separate MDD program at an unrelated company, and are not relevant to SP-624 [7]. Joel Raskin, the lead Phase 2 author, is Chief Medical Officer of Arrivo BioVentures, the development partner [9]. Next disclosure milestones are full results from NCT06254612 (expected H2 2026) and any End-of-Phase-2 meeting outcome.

SP-624 activates sirtuin 6 (SIRT6), an NAD+-dependent enzyme that removes chemical tags from histones, the spool-shaped proteins that DNA wraps around inside cells [2]. Think of SIRT6 as a maintenance worker for chromatin packaging: it adjusts which genes are accessible, and through that it tunes inflammation, glucose and lipid metabolism, and DNA repair. The depression hypothesis is that chronic stress drives changes in gene accessibility in brain cells that leave neurons stuck in a maladaptive state, and that boosting SIRT6 helps reset the system. This is a completely different theory from the serotonin and norepinephrine model that produced SSRIs and SNRIs. Mechanistic validation is thin. No SIRT6 activator is approved for any indication. The human genetics linking SIRT6 to depression are preliminary, and animal models of depression are weak predictors of clinical antidepressant effect in general. The 20 mg oral dose was selected based on Phase 1 PK; whether it achieves CNS exposures that meaningfully engage SIRT6 in human brain tissue has not been demonstrated with a target-engagement biomarker. The strength of the mechanism case therefore rests almost entirely on the clinical signal SP-624 itself produces. A clean Phase 2b/3 win would retroactively validate SIRT6 activation as a CNS strategy and likely pull other sirtuin programs into psychiatry. A miss leaves SIRT6 on the same pile as glutamatergic, opioid, and neurokinin antidepressant programs that produced interesting Phase 2 signals and failed to replicate.

NCT06254612 is a Phase 2b/3, multicenter, double-blind, randomized, placebo-controlled study in 456 adults with MDD, comparing forvisirvat 20 mg once daily to placebo over 4 weeks [3, 9]. Primary endpoint is change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) total score, the 10-item clinician-rated instrument used in essentially every modern antidepressant registration program. Placebo control without an active comparator is appropriate. MDD trials show placebo response rates often above 35%, and the regulatory path requires a placebo-controlled superiority result, not non-inferiority versus an SSRI. The 4-week treatment window is short for MDD where antidepressant signal typically accrues through Weeks 6 to 8; matching the earlier trial duration is consistent with confirming a Week 4 signal rather than testing durability. The earlier Phase 2 (NCT04479852, n=319) used the same 20 mg dose and Week 4 endpoint [4]. Per Raskin et al. and the Arrivo BioVentures clinical summary, the Week 4 MADRS comparison reached statistical significance in the overall population, but the signal was sex-stratified: 5 of 6 prespecified efficacy measures were statistically significant in female participants, while male participants did not show a treatment signal [1, 9]. Specific point estimates for MADRS least-squares mean difference, p-values, and placebo response rates are reported in the paywalled Raskin et al. paper [1]; the qualitative pattern (positive overall, female-driven) is what has been disclosed publicly. The fact that Sirtsei and Arrivo ran a second, larger Phase 2b/3 rather than moving straight to Phase 3 is consistent either with a sex-stratified Phase 2 that regulators wanted confirmed in a larger and prespecified design, or with effect-size noise that did not yet justify key investment.

The model estimates a 5% chance this drug is eventually approved. It starts from a historical base rate of about 24% for Phase 2 drugs in this area, then adjusts based on ten facts about the trial and sponsor. Larger-than-typical enrollment helps the estimate, while heavier-than-usual blinding, the sponsor's thin or weak approval record, and weak or limited earlier-phase results pull it down. The remaining factors fall near average for this stage and leave the estimate close to where the base rate placed it.

Efficacy is the dominant risk. The Phase 2 result was driven by the female subgroup, and a confirmatory trial that is powered on the overall population may fail to replicate a sex-stratified effect; sex-stratified signals are a recognized failure mode in MDD trials and were not the prespecified primary analysis in the n=319 study. MDD Phase 2 signals routinely dissolve in larger Phase 3 programs as placebo response climbs across more sites, and the MADRS endpoint is sensitive but noisy. The competitive bar is set by SSRIs and SNRIs that cost generic pennies, so even a statistically significant separation has to translate into a clinically meaningful difference patients and prescribers can feel. Safety risk is harder to size for a first-in-class mechanism. SIRT6 regulates DNA repair, glucose handling, and lipid metabolism in essentially every tissue [2]. The Phase 1 program reported acceptable tolerability through SAD and MAD dosing, but those exposures are short, and chronic dosing in a population that may stay on therapy for years is the real test. Execution risk is concrete: Sirtsei is privately held, with no SEC filings of its own and no publicly disclosed financing rounds; Arrivo BioVentures is the development partner but is also private. A Phase 3 MDD program typically runs north of $100 million. The combined Sirtsei and Arrivo entity will need either a larger partnership, an acquisition, or significant new financing to fund key trials. IP and exclusivity have not been publicly characterized in our sources; new chemical entity status would normally provide a 5-year regulatory exclusivity window from approval plus composition-of-matter patent life, but the specific patent estate and remaining term are not disclosed here and should be confirmed before underwriting commercial value. Commercial risk: even after approval, payers default to generic SSRIs and SNRIs first.

Worth watching, with one specific data point that decides everything: the placebo-adjusted MADRS change in the n=456 trial (NCT06254612) at Week 4, in the prespecified modified intent-to-treat population, with sex-stratified pre-planned analyses [3]. The threshold for taking SIRT6 seriously as a depression target is a separation of 3 points or more with a placebo response below 35% in the primary analysis, holding across both sexes rather than driven by females alone. Anything weaker, especially a result that requires the female subgroup to clear significance, fits the long history of MDD Phase 2 results that did not replicate. The Raskin et al. 2025 publication on the earlier 319-patient study is the most useful current document for calibrating expectations [1]; the public summary already discloses the sex-stratified pattern, but the specific MADRS least-squares mean difference, dose-response (single-dose study), responder rates, and tolerability detail are behind the journal paywall and should be pulled directly before any underwriting. Commercial benchmark: Auvelity (dextromethorphan and bupropion, Axsome Therapeutics) is the closest analog as the first oral novel-mechanism MDD approval of the post-SSRI era. Auvelity launched in 2022 at roughly $1,700 per month retail and has faced material payer step-edits requiring SSRI and SNRI failure first; Spravato (esketamine) requires REMS-monitored in-clinic administration, removing it from the oral-prescriber workflow that SP-624 would compete in. The realistic commercial path for SP-624 if approved is similar to Auvelity: branded pricing, payer pushback, slow uptake unless faster onset, durable remission, or activity in treatment-resistant or hard-to-treat depression can be demonstrated. Because Sirtsei and Arrivo are both privately held, the next informative signals outside the clinical readout are a Phase 3 initiation announcement, the outcome of an FDA End-of-Phase-2 meeting, or a partnership or financing deal that would fund key work. If none of those land within 12 to 18 months of the full Phase 2b/3 readout, the program has likely stalled regardless of what the trial showed. Note for the database: the Vistagen Therapeutics 10-K filings flagged in enrichment refer to PH94B (fasedienol), a different MDD asset at an unrelated company, and should not be linked to SP-624.